LCA President & CEO Testifies Before Congress On the Department of Defense Lung Cancer Research Program
May 20. 2010 [Washington, DC] -- Today, LCA President & CEO Laurie Fenton Ambrose testified before the House Appropriations Subcommittee on Defense on the newly established Lung Cancer Research Program within the Congressional Directed Medical Research Program. Fenton-Ambrose provided an overview of the scope of the problem and how the newly established research program, now in its second year with $35 million already appropriated, came to be established.
Citing the lack of sufficient research funding and the higher rates of incidence and mortality among military men and women as compared to their civilian counterparts, Fenton-Ambrose underscored the importance of this pipeline to fund the integrated components of early intervention and research for at risk military men and women.
Fenton-Ambrose stated that this program is intended to supplement, not duplicate research programs under the National Cancer Institute, with a particular focus on the patient and patient outcomes, that if properly implemented, will have an immediate impact on our high risk military and quickly lead to earlier detection and improved treatments for the entire population of those living with and those at risk for lung cancer.
She thanked the committee for their support for the program and urged the committee to appropriate additional funding for FY11.
To view the full testimony of Lung Cancer Alliance and its supporting documents, visit the links below:
Full Testimony of Lung Cancer Alliance to the House Appopriations Subcommittee on Defense
Lung Cancer Alliance Veterans and Military Fact Sheet
Cost of Care for Elderly Cancer Patients in the United States, Journal of the National Cancer Institutes
Future of Cancer Incidence in the United States, Journal of Clinical Oncology